Recently, Baili Tianheng announced its plan to repurchase a portion of its outstanding shares for an employee equity incentive program. This move aims to strengthen the company’s long-term incentive mechanism, attract and retain key talent, and enhance team cohesion and corporate competitiveness. According to the announcement, the company intends to use its own funds to repurchase shares via centralized bidding transactions, with a total repurchase amount not exceeding RMB 100 million. The repurchase price will not exceed 150% of the average closing price of the company’s stock over the 30 trading days prior to the board’s approval of the repurchase plan. All repurchased shares will be allocated exclusively for employee stock ownership or equity incentive schemes within three years. As a biopharmaceutical company focused on innovative drug development, Baili Tianheng has consistently increased its R&D investment in recent years. Implementing equity incentives helps align the interests of core employees with the company’s long-term strategic goals, thereby boosting motivation and driving sustainable growth. Additionally, the share repurchase signals management’s confidence in the company’s future prospects, which may bolster investor sentiment and support share price stability.
近日，百利天恒（Baili Tianheng）宣布拟回购公司部分已发行股份，用于实施员工股权激励计划。此举旨在进一步完善公司长效激励机制，吸引和留住核心人才，提升团队凝聚力与企业竞争力。根据公告，公司计划使用自有资金，以集中竞价交易方式回购股份，回购总金额预计不超过人民币1亿元，回购价格不超过董事会审议通过回购方案前30个交易日公司股票平均收盘价的150%。回购完成后，所购股份将全部用于员工持股计划或股权激励，并在三年内完成授予。作为一家专注于创新药物研发的生物医药企业，百利天恒近年来持续加大研发投入，此次通过股权激励绑定核心骨干，有助于激发员工积极性，推动公司长期战略目标的实现。同时，股份回购也向市场传递了公司对未来发展前景的信心，有望增强投资者信心并稳定股价表现。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/11263.html